September 8, 2009 (FinancialWire) — KV Pharmaceutical Co. (NYSE: KV-A) has named Thomas McHugh, the company’s vice president of finance and corporate controller, as its interim chief financial officer of the company.

McHugh replaces Ronald J. Kanterman, who ceased serving as the CFO of the company as of September 2. Kanterman continues to serve as a member of the KV Pharmaceutical board.

The company said it has initiated a search for a CFO and has formed a committee for that purpose. David A. Van Vliet, KV’s interim president and chief executive officer, and members of the board comprise the committee.

St. Louis-based KV Pharmaceutical is a specialty pharmaceutical company that develops, manufactures, markets, and acquires branded and generic prescription pharmaceutical products.

The company markets its products through Ethex Corp., a subsidiary that competes with branded products, and Ther-Rx Corp., the company’s branded drug subsidiary.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.